JEIL-KIRIN PHARMACEUTICAL

Jeil-Kirin Pharmaceutical is a prominent joint venture established in 1991 between South Korea's Jeil Pharmaceutical and Japan's Kyowa Kirin. The company focuses on the commercialization and distribution of specialized biopharmaceuticals within the South Korean market, primarily targeting therapeutic areas such as nephrology, oncology, and hematology. Its portfolio features several first-in-class and best-in-class biologics, including treatments for chronic kidney disease complications and rare genetic disorders like X-linked hypophosphatemia. By combining Kyowa Kirin's global R&D capabilities with Jeil Pharmaceutical's local distribution network, the company ensures patient access to innovative therapies. Jeil-Kirin Pharmaceutical maintains a strong market presence through its dedicated focus on high-need medical sectors and its commitment to improving healthcare outcomes in Korea.